Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
Mark J. Truty(Mayo Clinic in Arizona), Axel Grothey(Campbell Clinic), Sean P. Cleary(University Health Network), Michel G. Haddock(Radiation Oncology Associates), William S. Harmsen(Mayo Clinic), Rondell P. Graham(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), David M. Nagorney(Mayo Clinic in Arizona), Rory L. Smoot(Pancreas Centre (Canada)), Ajit H. Goenka(Mayo Clinic in Arizona), Þorvarður R. Hálfdánarson(Mayo Clinic), Amit Mahipal(Dana-Farber Cancer Institute), Michael L. Kendrick, Robert R. McWilliams(Mayo Clinic in Arizona)
Cited by 445
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k